Inalossin

Nitric Oxide, the active ingredient in Inalossin, is a gaseous donor presented as a gas for inhalation for inhalation use. It facilitates pulmonary vasodilation and improves oxygenation in specific respiratory conditions by releasing nitric oxide directly into the pulmonary circulation.

GNH USA supplies Inalossin as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, clinics and research institutions worldwide, with a focus on quality and regulatory compliance.

Inalossin is used in pulmonary vascular disorders where inhaled nitric oxide provides selective vasodilation.

Persistent Pulmonary Hypertension of the Newborn: improves oxygenation and reduces right‑to‑left shunt. Acute Respiratory Distress Syndrome: enhances ventilation‑perfusion matching and supports oxygenation. Pulmonary Hypertension in Adults: provides selective pulmonary vasodilation to lower pulmonary arterial pressure.

Inhaled nitric oxide may be associated with several adverse reactions, ranging from mild to severe.

Common Side Effects: - Hypotension: transient drop in systemic blood pressure. - Headache: mild to moderate intensity. - Dizziness or light‑headedness. - Flushing of the skin. - Nausea or mild gastrointestinal discomfort. - Cough or throat irritation.

Serious or Rare Side Effects: - Methemoglobinemia: elevated methemoglobin levels impairing oxygen delivery. - Rebound pulmonary hypertension upon abrupt discontinuation. - Severe hypotension requiring intervention. - Bronchospasm or airway irritation. - Hemorrhage related to anticoagulation. - Infection from contaminated delivery system.

When using Inalossin, clinicians should observe several safety considerations.

Pregnancy: safety not established; weigh potential benefits against risks. Contraindications: avoid in patients with severe anemia or known methemoglobinemia. Monitoring: continuously monitor methemoglobin levels and hemodynamics during therapy. Equipment: ensure proper delivery system and leak‑free connections. Store at ambient temperature: keep cylinder in original packaging, protect from heat and direct sunlight.

Inhaled nitric oxide can interact with other agents that affect vascular tone or hemoglobin.

Major Interactions (Avoid): - Phosphodiesterase‑5 inhibitors (e.g., sildenafil): may cause profound hypotension. - Other nitric oxide donors or inhaled vasodilators: risk of additive hypotensive effects. - Certain anesthetic gases (e.g., nitrous oxide): can potentiate vasodilation.

Moderate Interactions (Monitor Closely): - Systemic antihypertensives: may require dose adjustment. - Anticoagulants: monitor for increased bleeding risk if pulmonary hypertension worsens. - Beta‑blockers: observe for altered hemodynamic response.